FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129927968> ?p ?o ?g. }

• W2129927968 endingPage "438" @default.
• W2129927968 startingPage "431" @default.
• W2129927968 abstract "The overexpression of receptor tyrosine kinase EphA2 has been reported in various cancers. In non-small cell lung cancer (NSCLC), a positive correlation has been reported between high EphA2 immunohistochemical staining level and poor prognosis. However, its ligand, ephrin-A1, is supposed to act as a tumor suppressor via the kinase activity of EphA2. Thus, the biphasic roles of this system are not fully elucidated. We retrospectively evaluated the expression levels of EphA2 and ephrin-A1 in surgically treated pathological (p-) stage I NSCLC tumor samples, and their relation to clinicopathologic features or postoperative prognoses.The levels of EphA2 and ephrin-A1 mRNA expression were quantified by real-time reverse-transcription polymerase chain reaction in tissue samples from p-stage I NSCLC patients who had undergone complete resection in our facility (n=195). They were divided into two (EphA2/ephrin-A1-Low and -High) groups based on the median expression level, and their respective clinicopathologic features and prognoses were analyzed. Furthermore, samples were stained immunohistochemically and classified into four groups according to their staining levels, and their prognoses analyzed.Marked demographic differences were found between EphA2/ephrin-A1-Low and -High groups. Both EphA2-High and ephrin-A1-High groups had more females, no smoking history, adenocarcinoma histology, well-differentiated carcinomas, p-stage IA patients, and patients with EGFR gene mutations. Five-year overall survival rates of the EphA2-Low and the EphA2-High patient groups were 68.9% and 86.1%, respectively (P=0.017), and five-year disease-free survival rates were 69.9% and 83.2%, respectively (P=0.035). There were no statistical differences between ephrin-A1-Low and ephrin-A1-High groups concerning postoperative survival. Although showing smaller differences, the findings from the immunohistochemical analyses supported the above results.Higher expression of EphA2 and ephrin-A1 was more related to the female sex, reduced smoking status, adenocarcinoma, well differentiated carcinomas, p-stage IA, and EGFR gene mutations. Higher EphA2 mRNA expression in p-stage I NSCLC patients was positively related to improved prognoses. These results may reflect a tumor suppressive role for the EphA2/ephrin-A1 system in a population of patients restricted to p-stage I NSCLC." @default.
• W2129927968 created "2016-06-24" @default.
• W2129927968 creator A5010283962 @default.
• W2129927968 creator A5029663512 @default.
• W2129927968 creator A5030254292 @default.
• W2129927968 creator A5038493861 @default.
• W2129927968 creator A5041759783 @default.
• W2129927968 creator A5048136133 @default.
• W2129927968 creator A5053475533 @default.
• W2129927968 creator A5061399792 @default.
• W2129927968 creator A5067522479 @default.
• W2129927968 creator A5071175870 @default.
• W2129927968 creator A5085431281 @default.
• W2129927968 creator A5089403750 @default.
• W2129927968 date "2012-06-01" @default.
• W2129927968 modified "2023-09-26" @default.
• W2129927968 title "Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma" @default.
• W2129927968 cites W1536223993 @default.
• W2129927968 cites W1584018958 @default.
• W2129927968 cites W1639582946 @default.
• W2129927968 cites W1740332796 @default.
• W2129927968 cites W1964166386 @default.
• W2129927968 cites W1994094811 @default.
• W2129927968 cites W2000027123 @default.
• W2129927968 cites W2011907603 @default.
• W2129927968 cites W2017468311 @default.
• W2129927968 cites W2020830322 @default.
• W2129927968 cites W2033553319 @default.
• W2129927968 cites W2049547244 @default.
• W2129927968 cites W2053050910 @default.
• W2129927968 cites W2066300288 @default.
• W2129927968 cites W2078638255 @default.
• W2129927968 cites W2089398124 @default.
• W2129927968 cites W2093282771 @default.
• W2129927968 cites W2093776977 @default.
• W2129927968 cites W2094663537 @default.
• W2129927968 cites W2104662981 @default.
• W2129927968 cites W2109850440 @default.
• W2129927968 cites W2113211383 @default.
• W2129927968 cites W2115472066 @default.
• W2129927968 cites W2118444588 @default.
• W2129927968 cites W2129825215 @default.
• W2129927968 cites W2135743367 @default.
• W2129927968 cites W2139429540 @default.
• W2129927968 cites W2146479170 @default.
• W2129927968 cites W2149020768 @default.
• W2129927968 cites W2163798887 @default.
• W2129927968 cites W2168369189 @default.
• W2129927968 cites W2168691181 @default.
• W2129927968 cites W2171321297 @default.
• W2129927968 cites W4230112911 @default.
• W2129927968 cites W4239714259 @default.
• W2129927968 doi "https://doi.org/10.1016/j.lungcan.2011.12.004" @default.
• W2129927968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22236865" @default.
• W2129927968 hasPublicationYear "2012" @default.
• W2129927968 type Work @default.
• W2129927968 sameAs 2129927968 @default.
• W2129927968 citedByCount "38" @default.
• W2129927968 countsByYear W21299279682012 @default.
• W2129927968 countsByYear W21299279682013 @default.
• W2129927968 countsByYear W21299279682014 @default.
• W2129927968 countsByYear W21299279682015 @default.
• W2129927968 countsByYear W21299279682016 @default.
• W2129927968 countsByYear W21299279682018 @default.
• W2129927968 countsByYear W21299279682019 @default.
• W2129927968 countsByYear W21299279682020 @default.
• W2129927968 countsByYear W21299279682021 @default.
• W2129927968 countsByYear W21299279682022 @default.
• W2129927968 countsByYear W21299279682023 @default.
• W2129927968 crossrefType "journal-article" @default.
• W2129927968 hasAuthorship W2129927968A5010283962 @default.
• W2129927968 hasAuthorship W2129927968A5029663512 @default.
• W2129927968 hasAuthorship W2129927968A5030254292 @default.
• W2129927968 hasAuthorship W2129927968A5038493861 @default.
• W2129927968 hasAuthorship W2129927968A5041759783 @default.
• W2129927968 hasAuthorship W2129927968A5048136133 @default.
• W2129927968 hasAuthorship W2129927968A5053475533 @default.
• W2129927968 hasAuthorship W2129927968A5061399792 @default.
• W2129927968 hasAuthorship W2129927968A5067522479 @default.
• W2129927968 hasAuthorship W2129927968A5071175870 @default.
• W2129927968 hasAuthorship W2129927968A5085431281 @default.
• W2129927968 hasAuthorship W2129927968A5089403750 @default.
• W2129927968 hasBestOaLocation W21299279682 @default.
• W2129927968 hasConcept C101544691 @default.
• W2129927968 hasConcept C121608353 @default.
• W2129927968 hasConcept C126322002 @default.
• W2129927968 hasConcept C142724271 @default.
• W2129927968 hasConcept C143998085 @default.
• W2129927968 hasConcept C146357865 @default.
• W2129927968 hasConcept C150582083 @default.
• W2129927968 hasConcept C151730666 @default.
• W2129927968 hasConcept C170286479 @default.
• W2129927968 hasConcept C170493617 @default.
• W2129927968 hasConcept C19331615 @default.
• W2129927968 hasConcept C204232928 @default.
• W2129927968 hasConcept C207886595 @default.
• W2129927968 hasConcept C2776256026 @default.
• W2129927968 hasConcept C2777546739 @default.

• next